Eric Fortin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eric Fortin has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Chloe Gottlieb
University of Ottawa Eye Institute, University of Ottawa
2 shared publications - Deborah M. Levy
Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada
2 shared publications - Roberta Audrey Berard
London Health Sciences Centre and Western University London Ontario Canada
2 shared publications - Alan M. Rosenberg
Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
1 shared publication Albert T. Vitale
Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah
1 shared publication- Alexandra P. Song
AbbVie Inc., North Chicago, Illinois, United States
1 shared publication
Latest Publications
- Open Access
- 1 July 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (12) , 1647-1648
Dr. Gottlieb et al reply
We thank the author for their reply1 and appreciate the approach of having clear terminology and standard definitions within clinical practice guidelines or recommendations, that are applicable across specialist groups. A definition of controlled anterior uveitis or quiescent disease is important for treatment decisions, particularly when classifying a patient9s disease as failing current therapy and making decisions for escalating therapy.
- 1 July 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (12) , 1647-1648
Open AccessDr. Gottlieb et al reply
We thank the author for their reply1 and appreciate the approach of having clear terminology and standard definitions within clinical practice guidelines or recommendations, that are applicable across specialist groups. A definition of controlled anterior uveitis or quiescent disease is important for treatment decisions, particularly when classifying a patient9s disease as failing current therapy and making decisions for escalating therapy.
- 15 October 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (3) , 390-399
Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis
Objective To develop Canadian recommendations for the screening, monitoring and treatment of uveitis associated with Juvenile Idiopathic Arthritis (JIA). Methods Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Adolopment approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including EtD tables, survey responses, and virtual meeting discussion. Results The survey identified that 7 of the nineteen recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of non-biologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo. Conclusion Recommendations for JIA-associated uveitis were adapted to the Canadian context by a Working Group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis and parent/patient input utilizing lenses for cost, equity, and access.
- 15 October 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (3) , 390-399
Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis
Objective To develop Canadian recommendations for the screening, monitoring and treatment of uveitis associated with Juvenile Idiopathic Arthritis (JIA). Methods Recommendations were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-Adolopment approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including EtD tables, survey responses, and virtual meeting discussion. Results The survey identified that 7 of the nineteen recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of non-biologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo. Conclusion Recommendations for JIA-associated uveitis were adapted to the Canadian context by a Working Group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis and parent/patient input utilizing lenses for cost, equity, and access.
- Open Access
- 1 June 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (6) , 899-909
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
- 1 June 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (6) , 899-909
Open AccessLong-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis